Last reviewed · How we verify

Novartis Seasonal Influenza Vaccine

Seqirus · Phase 3 active Biologic

Novartis Seasonal Influenza Vaccine is a vaccine Biologic drug developed by Seqirus. It is currently in Phase 3 development for Prevention of seasonal influenza in individuals aged 6 months and older.

The vaccine stimulates the immune system to produce antibodies against specific influenza virus strains, thereby preventing infection.

The vaccine stimulates the immune system to produce antibodies against specific influenza virus strains, thereby preventing infection. Used for Prevention of seasonal influenza in individuals aged 6 months and older.

At a glance

Generic nameNovartis Seasonal Influenza Vaccine
SponsorSeqirus
Drug classvaccine
ModalityBiologic
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

Upon administration, the vaccine introduces inactivated or attenuated influenza viruses or their components, which trigger an immune response. This leads to the production of antibodies that can recognize and neutralize the virus if encountered in the future.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Novartis Seasonal Influenza Vaccine

What is Novartis Seasonal Influenza Vaccine?

Novartis Seasonal Influenza Vaccine is a vaccine drug developed by Seqirus, indicated for Prevention of seasonal influenza in individuals aged 6 months and older.

How does Novartis Seasonal Influenza Vaccine work?

The vaccine stimulates the immune system to produce antibodies against specific influenza virus strains, thereby preventing infection.

What is Novartis Seasonal Influenza Vaccine used for?

Novartis Seasonal Influenza Vaccine is indicated for Prevention of seasonal influenza in individuals aged 6 months and older.

Who makes Novartis Seasonal Influenza Vaccine?

Novartis Seasonal Influenza Vaccine is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).

What drug class is Novartis Seasonal Influenza Vaccine in?

Novartis Seasonal Influenza Vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is Novartis Seasonal Influenza Vaccine in?

Novartis Seasonal Influenza Vaccine is in Phase 3.

What are the side effects of Novartis Seasonal Influenza Vaccine?

Common side effects of Novartis Seasonal Influenza Vaccine include Injection site pain, Fatigue, Headache.

Related